Table 1.
Clinicopathological features of the 95 GBM (glioblastoma) patients, comparing low integrin α5 and high integrin α5 groups according to median expression level (median of MMFI) as the cut-off threshold.
| Clinicopathological Features | Total No. of Patients | With | With | |
|---|---|---|---|---|
| Low α5 | High α5 | p-Value * | ||
| Expression | Expression | |||
| n | 95 | 47 | 48 | |
| Age, n (%) | ||||
| ≥60 | 36 (38) | 19 (40) | 17 (35) | 0.6752 |
| <60 | 59 (62) | 28 (60) | 31 (65) | |
| Gender, n (%) | ||||
| Male | 61 (64) | 26 (55) | 35 (73) | 0.0891 |
| Female | 34 (36) | 21 (45) | 13 (27) | |
| Resection degree, n (%) | ||||
| Biopsy | 20 (21) | 6 (13) | 14 (29) | |
| Partial resection | 34 (36) | 18 (38) | 16 (33) | 0.1410 |
| Macroscopic resection | 41 (43) | 23 (49) | 18 (38) | |
| RPA score, n (%) | ||||
| <V | 37 (39) | 17 (36) | 20 (42) | |
| ≥V | 37 (39) | 19 (40,5) | 18 (37) | 0.8575 |
| Unknown | 21 (22) | 11 (23,5) | 10 (21) | |
| MGMT promoter status, n (%) | ||||
| Methylated | 31 (33) | 17 (36) | 14 (29) | |
| Un-methylated | 28 (29) | 14 (30) | 14 (29) | 0.6962 |
| Unknown | 36 (38) | 16 (34) | 20 (42) | |
| P53 gene status, n (%) | ||||
| Mutated (antigen detected in >10% cells) | 13 (14) | 3 (6) | 10 (21) | |
| Wild-type (<10% cells) | 5 (5) | 2 (4) | 3 (6) | 0.0912 |
| Unknown | 77 (81) | 42 (90) | 35 (73) | |
| Stupp protocol, n (%) | ||||
| Completed | 58 (61) | 28 (60) | 30 (63) | |
| Un-completed | 24 (25,5) | 12 (25) | 13 (27) | 0.4670 |
| None | 4 (4) | 1 (2) | 2 (4) | |
| Unknown | 9 (9,5) | 6 (13) | 3 (6) | |
| Recurrence treatment, n (%) | ||||
| None | 35 (37) | 14 (30) | 21 (44) | |
| Second-line treatment | 40 (42) | 19 (42) | 20 (42) | |
| -Chemotherapy | 30 (32) | 14 (30) | 16 (33) | 0.2103 |
| -Bevacizumab | 23 (24) | 9 (19) | 14 (29) | |
| Unknown or NA | 20 (21) | 14 (30) | 7 (15) | |
| α5 expression level (A.U.) Mean ± SE | 320 ± 17 | 213 ± 4 | 425 ± 28 | p < 0.0001 |
MMFI: Mean of mean fluorescence intensity; RPA: recursive partitioning analysis; MGMT: O-6-methylguanine-DNA methyltransferase; TMZ: temozolomide; BEV: bevacizumab; AU: arbitrary unit; NA: not applicable; SE: standard error *. Chi-square test was used to evaluate independency between clinico-pathological features and integrin α5 expression level, and Mann–Whitney test was used to compare expression level (MMFI) of integrin α5 between low- and high-expression subgroups.